Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ACE1831 + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ACE1831||ACE-1831|ACE 1831||ACE1831 is an antibody conjugated effector cell therapy comprising an anti-CD20 antibody conjugated to gamma delta T-lymphocytes, which potentially leads to tumor cell killing (Cancer Res 2022;82(12_Suppl):Abstract nr 5573).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05653271||Phase I||ACE1831 + Cyclophosphamide + Fludarabine + Obinutuzumab ACE1831 + Cyclophosphamide + Fludarabine||ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies||Recruiting||USA||0|